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Microbiology of Urinary Tract Infections in Gaborone, Botswana
Abstract
Objective
The microbiology and epidemiology of UTI pathogens are largely unknown in Botswana, a high prevalence
HIV setting. Using laboratory data from the largest referral hospital and a private hospital, we describe the
major pathogens causing UTI and their antimicrobial resistance patterns.
Methods
This retrospective study examined antimicrobial susceptibility data for urine samples collected at Princess
Marina Hospital (PMH), Bokamoso Private Hospital (BPH), or one of their affiliated outpatient clinics. A
urine sample was included in our dataset if it demonstrated pure growth of a single organism and
accompanying antimicrobial susceptibility and subject demographic data were available.
Results
A total of 744 samples were included. Greater than 10% resistance was observed for amoxicillin, co-
trimoxazole, amoxicillin-clavulanate, and ciprofloxacin. Resistance of E. coli isolates to ampicillin and co-
trimoxazole was greater than 60% in all settings. HIV status did not significantly impact the microbiology of
UTIs, but did impact antimicrobial resistance to co-trimoxazole.
Conclusions
Data suggests that antimicrobial resistance has already emerged to most oral antibiotics, making empiric
management of outpatient UTIs challenging. Ampicillin, co-trimoxazole, and ciprofloxacin should not be
used as empiric treatment for UTI in this context. Nitrofurantoin could be used for simple cystitis;
aminoglycosides for uncomplicated UTI in inpatients.
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60% in all settings. HIV status did not significantly impact the microbiology of UTIs, but did impact antimicrobial resistance
to co-trimoxazole.
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Introduction
Urinary tract infections (UTI) are considered to be the most
common bacterial infection, and it is estimated that they affect up
to 150 million individuals annually [1,2]. There are limited data
on the true impact of UTIs in the developing world. In the USA,
UTIs are responsible for 7 million physician visits and more than
100,000 hospital admissions annually [3]. The total annual direct
and indirect cost due to UTIs in the US alone is estimated to be
greater than US$ 1.6 billion [3]. Globally, they cause not only
a significant amount of morbidity, but also a significant financial
burden [2,4].
The introduction of antimicrobial therapy has led to profound
improvements in the management of urinary tract infections;
however antimicrobial resistance is a growing problem and a cause
of major concern in many countries [4–6]. The main causative
agents of UTI are Gram-negative bacteria, notably Escherichia coli,
however other Enterobacteriaceae and Staphylococcus saprophyticus
are also commonly involved [7,8]. Over the past several decades,
resistance to many of the commonly prescribed UTI antibiotics -
ampicillin, co-trimoxazole, nitrofurantoin, and fluoroquinolones -
has emerged [9].
Recent clinical guidelines emphasize the importance of knowing
local patterns of susceptibility of coliforms to antimicrobial agents
[6,10]. To date, there have been no studies describing the
microbiology and epidemiology of pathogens causing urinary tract
infection among pediatric and adult populations in Botswana,
a medium income sub-Saharan African setting with a relatively
well-developed primary health care system and a total population
prevalence of HIV of 17.6% [11]. Our primary objective was to
describe the major pathogens causing UTI among pediatric and
adult populations, as well as the patterns of antimicrobial
resistance locally, with the ultimate aim of guiding empiric
therapy. Secondary objectives were to compare differences in these
patterns within the public and private healthcare sectors, as well as
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within inpatient and outpatient settings. Additionally, we sought to
explore the impact of HIV status on UTI pathogens and antibiotic
resistance patterns.
Methods
Ethics Statement
Ethical approval was granted by the institutional review boards
at the Botswana Ministry of Health, Princess Marina Hospital
(PMH), Bokamoso Private Hospital (BPH) and the University of
Pennsylvania. These IRBs also granted waivers of consent, as all
data was retrospectively collected and deidentified on our data
collection sheets to ensure patient confidentiality.
This was a retrospective study of antimicrobial susceptibility
data for urine samples collected at PMH, BPH, or one of their
affiliated outpatient clinics. PMH has 525 beds and is the main
public tertiary-care hospital in Botswana’s capital city, Gaborone,
while BPH has 200 beds and is a private primary, secondary and
tertiary-care hospital also located in the capital. Affiliated clinics
are located throughout the greater Gaborone area and serve
a population of around 300,000 people.
For PMH, we reviewed laboratory records of urine specimens
submitted for investigations from patients who presented between
January 1, 2007 and December 31, 2009. Samples from BPH,
which opened on January 11, 2010 were collected between
January 11, 2010 and December 31, 2010. For both hospitals, we
included urine samples for patients who were admitted to various
inpatient wards, as well as patients who had samples collected at
affiliated outpatient clinics. All samples were collected as part of
routine patient care.
A urine sample was included in our dataset if it demonstrated
growth of a single organism with accompanying antimicrobial
susceptibility, and subject demographic data were available. For
patients with more than one sample, we included only the first
positive sample with susceptibility data. Samples were excluded
from the dataset if there were duplicate samples with differing
sensitivities, if there were duplicate samples listed under multiple
years, or if samples grew multiple pathogens.
Urine microscopy, isolation, and identification of organisms
were carried out as part of the routine procedures in the
microbiology laboratories at PMH and BPH. Antimicrobial
susceptibility testing was conducted at PMH via disc diffusion
method according to the Clinical and Laboratory Standards
Institute (CLSI) guidelines [12]. Additional testing for extended
spectrum beta-lactamase (ESBL) production was not available at
PMH during the time period included in the study. BPH used the
MicroScan WalkAway automated system (Siemens Healthcare
Diagnostics), which included screening for Extended-Spectrum
Beta-Lactamase (ESBL) production. Confirmatory testing for
ESBL production was carried out using disc diffusion according
to CLSI guidelines (CLSI) [12].
Additional data collected included patient age, sex, HIV status
and clinical setting.
Analysis was performed using standard descriptive statistics and
STATA version 11.1 (College Station, TX). Proportions of
resistance were compared using Fisher’s exact and chi-squared
tests and p,0.05 was deemed significant.
Results
At PMH, 680 urine culture samples were evaluated for
inclusion. Samples were not cultured if urinalysis was normal.
Twenty-eight samples were excluded for the following reasons: a)
duplicate samples with matching specimen and medical record
numbers, but differing sensitivities (sample with most complete
sensitivity data was included) (n = 8); b) duplicate samples with
matching medical record numbers and specimen numbers, but
with multiple years listed (correct year was confirmed via
electronic medical records and duplicate was excluded) (n = 9); c)
samples that grew multiple pathogens (n = 52). A total of 652
samples were included from PMH, which included all samples that
met our inclusion criteria. Of the samples from PMH, 58% were
from outpatient clinics.
At BPH, 760 samples were evaluated for inclusion from BPH.
We included a total of 92 samples, with the remainder excluded
for either no growth of a single organism, or growth of multiple
organisms. The low culture positivity rate at BPH vs PMH may be
explained by the fact that specimens were often cultured at BPH
without a prior microscopy or dip or despite a negative microscopy
or dip. Seventy-three percent of eligible samples from BPH were
from outpatient clinics.
Urine dipsticks, as well as urine microscopy, culture, and
sensitivities, were carried out inconsistently at both institutions.
Cultures at PMH were generally performed on samples with .10
white blood cells (WBC) per high power field (hpf) on microscopy;
however, some had cultures performed if they were only positive
on dipstick testing for blood, leukocyte esterase, or nitrites.
Sometimes cultures were performed without prior microscopy or
with normal microscopy.
Information on patient demographics is listed in Table 1. There
were no significant differences in the age distribution or gender of
patients when comparing the private and public sectors. Inpatients
were more likely to be male (P= 0.002) and to be less than 18 years
old or 65 years and older (P,0.001). There were broadly
equivalent percentages of HIV-positive patients in the public
and private settings, although patients were more likely to have an
unknown or undocumented HIV status at PMH (P,0.001).
However, at PMH, almost half (49%) of the patients with known
HIV status were HIV-positive compared to just over a quarter
(26%) at BPH (P= 0.002).
Uropathogens from PMH and BPH are listed in Table 2. There
were significant differences in the pathogens isolated when
comparing private to public settings (P = 0.001) and inpatient to
outpatient settings (P = 0.007). E. coli was the most common
pathogen in all settings and accounted for 63% of isolates at both
PMH and BPH. Sixty-six percent of outpatient isolates were E.
coli, compared to 58% in inpatient settings. At PMH, Klebsiella
species were responsible for 14% of UTIs followed by Proteus
species that were responsible for another 5%. Klebsiella and Proteus
species each accounted for 7% of isolates at Bokamoso.
At BPH, 10 isolates (11%) were found to produce ESBL. Six
were E. coli isolates, three were Proteus isolates, and one was
a Klebsiella isolate.
Figure 1 illustrates overall resistance patterns for all uropatho-
gens stratified by study site. Given that it was the predominant
organism, analysis focused on resistance patterns of E. coli isolates
(Figure 2). Among E. coli isolates, there was no significant
difference in resistance to ampicillin when comparing samples
from in- and outpatient settings. However, resistance was
significantly higher among samples from patients at PMH
compared to those from BPH (86% vs. 76%; P= 0.034). Re-
sistance to gentamicin was higher among samples from inpatients
compared to outpatients (P = 0.015) and the public sector
compared to the private sector (P = 0.018). Resistance to co-
trimoxazole was also higher among samples from inpatients
(P = 0.017) and the public sector (P = 0.034). Nearly 30% of E. coli
isolates at PMH were resistant to amoxicillin/clavulanate com-
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pared with 11% from BPH (P= 0.016). However, another 13% of
samples from BPH demonstrated intermediate resistance.
Resistance patterns to nitrofurantoin, ceftazidime, and cipro-
floxacin did not differ significantly based on setting (P.0.05).
Overall resistance to nitrofurantoin was ten percent or lower in all
settings. Twenty-five percent of E. coli isolates were resistant to
ciprofloxacin in the inpatient settings in both the public and
private sectors with somewhat lower resistance in outpatient
settings.
Data were not available for resistance patterns of first- or
second-generation cephalosporins at PMH. There was no
significant difference in resistance patterns for cefazolin or
cefuroxime at BPH when comparing inpatient and outpatient
settings (P.0.05). There was 18 percent resistance to both
cefazolin and cefuroxime among E. coli isolates at BPH, with an
additional 10 percent and three percent showing intermediate
resistance respectively.
Sub-analyses also compared the differences in microbiology and
antimicrobial susceptibilities between samples from pediatric (,18
years old) and adult populations. There were no significant
differences in the pathogens causing UTI when comparing these
populations. However, compared to those from adult patients, E.
coli isolates from pediatric patients did have higher levels of
resistance to gentamicin (23% vs 11%) (P= 0.045) and co-
trimoxazole (88% vs 74%) (P= 0.031).
We further explored the association between known HIV status,
uropathogens, and antimicrobial resistance of E. coli isolates. HIV
status had no significant impact on the uropathogens that caused
UTI in any setting. However, HIV status was associated with
a difference in the resistance of E. coli isolates to co-trimoxazole. E.
Table 1. Patient Demographics.
Princess Marina Hospital (n = 652) Bokamoso Hospital (n = 92)
Inpatient Outpatient Total Inpatient Outpatient Total
Age (yrs) Median
(IQR)
37 (26–56) 28 (22–41) 32 (23–49) 50 (36–62) 36 (29–47) 37 (30–55)
,18 yrs 13% 9% 10% 4% 12% 10%
18–65 yrs 70% 85% 78% 80% 76% 77%
.65 yrs 17% 7% 11% 16% 12% 13%
Gender
Female 57% 68% 63% 72% 70% 71%
Unknown 1% 3% 2% 0% 0% 0%
HIV Status
Negative 25% 5% 13% 36% 42% 40%
Positive 20% 8% 13% 36% 6% 14%
Unknown 55% 87% 74% 28% 52% 46%
doi:10.1371/journal.pone.0057776.t001
Table 2. Uropathogens.
Princess Marina Hospital Bokamoso Hospital
Inpatient (n=276) Outpatient (n =376) Total (n = 652) Inpatient (n=25) Outpatient (n =67) Total (n = 92)
E. coli 58% 66% 63% 52% 67% 63%
Klebsiella spp. 16% 12% 14% 16% 3% 7%
Proteus spp. 7% 4% 5% 4% 7% 7%
Coagulase negative
S. aureus
4% 4% 4% 0 3% 2%
Streptococcus spp. 1% 4% 3% 0 0 0
S. aureus 2% 3% 2% 0 1% 1%
Enterobacter spp. 3% 2% 2% 4% 1% 2%
Enterococcus spp. 3% 2% 2% 4% 4% 4%
Citrobacter spp. 2% 2% 2% 4% 4% 4%
Morganella morganii 1% 1% 1% 0 0 0
Group B Streptococcus 1% 1% 1% 4% 4% 4%
Pseudomonas spp. 1% 0 1% 12% 0 3%
S. saprophyticus 0 1% ,1% 0 3% 2%
Salmonella spp. ,1% 0 ,1% 0 0 0
doi:10.1371/journal.pone.0057776.t002
Microbiology of UTI in Botswana
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coli isolates from known HIV-positive patients demonstrated
significantly higher resistance to co-trimoxazole compared to
isolates from known HIV-negative patients (95% vs. 72%)
(P,0.001). HIV status did not affect resistance patterns to the
other antimicrobials that we examined.
Discussion
E. coli accounted for more than 60% of urinary isolates in both
the public and private sectors in this study. Klebsiella and Proteus
species were the next most common pathogens isolated. These data
are consistent with findings from work in neighboring South Africa
[4,13].
Resistance of E. coli isolates to ampicillin and co-trimoxazole
was high across all settings although there were statistically
significant differences according to locale. E. coli isolates from the
public sector demonstrated higher levels of resistance to both
antibiotics compared to the private sector. Isolates from inpatients
were more likely to demonstrate resistance to co-trimoxazole
compared to outpatient samples. This latter difference could
largely be explained by HIV status and it is highly likely in
a Botswana setting that inpatients have a higher HIV prevalence
than outpatients. E. coli isolates from HIV-positive patients
demonstrated higher resistance to co-trimoxazole compared to
those samples from patients known to be HIV-negative. This is
likely due to the common use of co-trimoxazole for the treatment
of and prophylaxis against Pneumocystis jirovecii pneumonia among
HIV-positive patients.
Recent work in Nigeria has explored the association between
HIV status and UTI [14]. Omoregie and Eghafona demonstrated
that known HIV-positive patients on HAART had a higher
prevalence of asymptomatic UTI compared to HIV-negative
patients, although there was no association between CD4+ count
and asymptomatic UTI [14]. Our work demonstrates that in the
greater Gaborone region, HIV status does not affect the types of
pathogens causing UTI. Furthermore, HIV status was not
associated with any differences in antibiotic resistance levels,
except in the case of co-trimoxazole.
There were a number of limitations in our study that are
intrinsic to a study with a retrospective design. Specifically, the
diagnosis of UTI would have benefitted from consistent recording
of a urine dipsticks, as well as urine microscopy, culture, and
sensitivities. However, these were carried out inconsistently at both
institutions and represent an opportunity to improve overall care.
Additionally, there were inconsistencies in record keeping at
PMH. Laboratory data were intermittently recorded in either
paper logbooks or in electronic databases - therefore there are
some missing data from our analyses that might have impacted our
results. Missing data may also have affected our analysis of HIV
status. Almost three-quarters of patients at PMH and nearly half of
patients at BPH had an undocumented HIV status at the time
their urine samples were sent and these samples could not be
included in the HIV analysis. These limitations would be
adequately addressed through improved prospective UTI surveil-
lance strategies at both sites.
Figure 1. Antimicrobial resistance patterns of all UTI pathogens.* *Less than 15 samples analyzed for these antimicrobials as noted: PMH-
Outpatients (ciprofloxacin, ceftazidime).
doi:10.1371/journal.pone.0057776.g001
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Conclusions
The epidemiology of UTIs in Botswana appears in general to be
similar to that found in much of the world. HIV status did not
seem to significantly impact the microbiology of UTIs in our
context but did impact antimicrobial resistance to co-trimoxazole.
Findings from this retrospective study suggest that antimicrobial
resistance has already emerged to most oral agents. Greater than
10% resistance was observed for amoxicillin, co-trimoxazole,
amoxicillin/clavulanate, and ciprofloxacin. This makes empiric
management of outpatient UTIs challenging. Resistance of E. coli
isolates to ampicillin and co-trimoxazole was greater than 60% in
all settings examined in our study. These agents should not be used
as empiric treatment for UTI in the context of Botswana.
Additionally, given that there was greater than 20% resistance to
ciprofloxacin among inpatient E. coli isolates, its use would
otherwise be inappropriate as an empiric agent in this setting.
Overall resistance to nitrofurantoin was low in all settings,
suggesting that it could be used as empiric monotherapy for simple
cystitis. Aminoglycosides are an appropriate alternative in the
inpatient setting when there is not a concern regarding nephro-
toxicity and when enteral therapy is not an option and bacteremia
is not suspected.
A standardized approach to the diagnostic workup of patients
with suspected UTI in these settings would likely improve overall
care. In addition, improved record keeping and a prospective
surveillance system are needed in these Botswana hospitals in
order to facilitate regular surveillance of antibiotic resistance as
these levels continue to change.
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